Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: The placebo-controlled randomised phase III RUBY trial

ESMO Virtual Plenary

Session date: 27-28 March 2023

Login to get immediate access to this content.

Login

Abstract

VP2-2023: Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Published: March 27, 2023
DOI: https://doi.org/10.1016/j.annonc.2023.02.008
Download PDF

M.R. Mirza, D. Chase, B.M. Slomovitz, ... R.L. Coleman, M.A. Powell
Show authors and affiliations

Background

Carboplatin-paclitaxel (CP) is standard of care (SOC) for first-line treatment of primary A/R EC; median OS is <3 yrs. Use of anti–PD-1s with chemo has improved outcomes in multiple tumour types. RUBY (NCT03981796) evaluated the efficacy and safety of the anti–PD-1 dostarlimab (D)+CP in A/R EC compared with CP alone.

Methods

RUBY is a phase III, global, randomised, double-blind, multicentre, PBO-controlled study. Pts with primary advanced stage III or IV or first recurrent EC were randomised 1:1 to receive dostarlimab 500 mg, or PBO, plus carboplatin AUC 5 and paclitaxel 175 mg/m2 Q3W (6 cycles), followed by dostarlimab 1000 mg, or PBO, monotherapy Q6W for up to 3 yrs. Primary endpoints were PFS by investigator assessment per RECIST v1.1 and OS. Graphical method was used for hypothesis testing of PFS in the dMMR/MSI-H population, then the overall population, and OS in the overall population. A prespecified exploratory analysis of PFS in MMR proficient (MMRp)/MS stable (MSS) pts was also performed. Safety was assessed.

Results

Of 494 pts randomised (245 D+CP; 249 PBO+CP), 23.9% had dMMR/MSI-H tumours (53 D+CP; 65 PBO+CP), 47.8% had recurrent disease; 18.6% and 33.6% had primary stage III and IV disease, respectively. PFS and OS results are presented in the table. Discontinuation of dostarlimab or PBO due to a TEAE occurred in 17.4% pts receiving D+CP and 9.3% pts receiving PBO+CP. The safety profile of D+CP was generally consistent with the safety profile of each drug.

Conclusions

D+CP showed statistically significant and clinically meaningful PFS benefits in the dMMR/MSI-H and overall populations vs CP alone. A clinically relevant benefit in PFS was also observed in the MMRp/MSS population. An early trend toward improved OS was observed in all populations. The combination of dostarlimab+CP represents a new SOC for pts with newly diagnosed primary A/R EC.

Clinical trial identification

NCT03981796.

Simultaneous publication in the New England Journal of Medicine

Mansoor R. Mirza, Dana M. Chase, Brian M. Slomovitz, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial CancerN Engl J Med 2023; 23 March 2023. doi: 10.1056/NEJMoa2302312

ESMO Daily Reporter news article

First-line immunotherapy prolongs survival in advanced or recurrent endometrial cancer

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.